How do we sequence and combine novel agent-based therapies in CLL?
Ibrutinib in treatment for refractory or relapsed CLL
The 2016 International Workshop of the German CLL Study Group (GCLLSG)
The future of AML and MDS diagnosis and treatment
Stéphane de Botton
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?